Результаты поиска

Denosumab Related Osteonecrosis of the Jaw with Spontaneous Necrosis of the Soft Palate: Report of a Life Threatening Case.

Bisphosphonates have been used for years in the treatment of patients with distant bony metastasis and in the prevention of osteoporosis. One of main side effects of these medications is the development of bisphosphonate related osteonecrosis of the jaw (BRONJ) in a small subset of patients. A new class of medications with a shorter half-life, known as receptor activator of nuclear factor kappa-B ligand (RANKL) inhibitors, was introduced with the hopes of avoiding this side effect. However, reports of osteonecrosis of the jaw after the use of RANKL inhibitors have also been documented. We repo

Совпадение в полном тексте источника
… She received multiple platelet transfusions for thrombocytopenia with a count 63 × 10 3 /mm 3 on arrival and a nadir of 16 × 10 3 /mm 3 (unit) during her 10-day hospital stay. …

The 44th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians Oral Session

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Cancer of the prostate presenting with diffuse osteolytic metastatic bone lesions: a case report.

UnlabelledIntroductionProstate cancer is the second most common cancer in men and the fifth most common cancer worldwide. In the USA it is more common in African-American men than in Caucasian men. Prostate cancer frequently metastasizes to bone and the lesions appear osteoblastic on radiographs. Presentation with diffuse osteolytic bone lesions is rare. We describe an unusual presentation of metastatic prostate cancer with diffuse osteolytic bone lesions.Case presentationA 65-year-old Namibian man presented with anemia, thrombocytopenia and worsening back pains. In addition he had complaints

Carfilzomib-Induced Thrombotic Microangiopathy: A Case Report on a Rare Complication.

Thrombotic microangiopathy (TMA) is characterized by microangiopathic hemolytic anemia, thrombocytopenia, and organ injury due to microvascular thrombosis. Drug-induced TMA is a recognized subtype, but its diagnosis is challenging due to the absence of specific laboratory tests to identify the agent. Many chemotherapeutic agents are associated with TMA. Carfilzomib is a newer chemotherapeutic agent and is an uncommon cause of TMA. We report the case of a 71-year-old female patient undergoing treatment with carfilzomib for refractory multiple myeloma who developed suspected carfilzomib-induced

Совпадение в полном тексте источника
… She received two units of platelet transfusions and started on Tamiflu and intravenous fluids. Despite supportive care, her renal function deteriorated, prompting nephrology consultation. …

Более глубокая глубина реакции после выживания терапия улучшает результаты автономной трансплантации стволовых клеток в восстановленной лимфоме и возможность неконтролируемого замораживания периферальных стволовых клеток крови.

Высокодисперсная химиотерапия, за которой следует аутологическая трансплантация стволовых клеток, считается стандартным подходом к лечению пациентов с повторной лимфомой Ходжкина (HL) и неходгкинской лимфомой (NHL). Цель аутологической трансплантации стволовых клеток в рецидивированной лимфоме заключается в обеспечении долгосрочного контроля за заболеваниями, т.е. в лечении, в отличие от таких расстройств, как множественная миелома, где она лишь продлевает период ремиссии, без прогрессирования выживает и улучшает качество жизни. Опубликованные результаты высокодозированной терапии и АОПП, а та

Treatment-Associated Acute Lymphoblastic Leukemia Following Autologous Hematopoietic Stem Cell Transplant and Lenalidomide Maintenance in Patients With Multiple Myeloma.

Secondary malignancies including leukemia are an increasing concern in patients with prior primary malignancies treated with alkylating agents or topoisomerase II inhibitors. These can also be referred to as therapy-related leukemia. Therapy-related leukemia most commonly results in myelodysplastic syndrome or acute myeloid leukemia. The alkylating agent can cause chromosomal aberrations typically manifest as deletions in chromosome 11 or loss of part of complete loss of chromosomes 5 and 7. Conversely, acute lymphoblastic leukemia (ALL) has been described following maintenance therapy with im

Совпадение в полном тексте источника
… He received red blood cell and platelet transfusions as needed and GCSF was administered per protocol beginning T+5 until engraftment occurred. After recovery from transplant, he initiated on lenalidomide, maintenance therapy. The patient remained stable on this regimen with close follow-up. … He transitioned to best supportive care and required multiple packed red blood cell and platelet transfusions. He subsequently succumbed to his leukemia soon after treatment was discontinued. Treatment and outcomes are summarized in Table 2 . Table 1 Cytogenetics and FISH. …

Genetic and Functional Evidence of Complement Dysregulation in Multiple Myeloma Patients with Carfilzomib-Induced Thrombotic Microangiopathy Compared to Controls.

BACKGROUND: Carfilzomib, an irreversible proteasome inhibitor approved for the treatment of relapsed/refractory Multiple Myeloma (MM) has been associated with Thrombotic Microangiopathy (TMA). Several pathogenetic mechanisms of carfilzomib-induced TMA have been proposed; however, recently, there has been a shift of focus on the potential contribution of complement dysregulation. Our aim was to explore whether patients with carfilzomib-induced TMA harbor germline variants of complement-related genes, which have been characterized as risk factors for TMA. METHODS: We retrospectively recruited c

Selinexor in relapsed/refractory multiple myeloma.

Multiple myeloma (MM) represents an incurable hematologic malignancy. Despite significant advances over the past decade, with the advent of multiple new classes of anti-myeloma agents, including immunomodulatory drugs, proteasome inhibitors and monoclonal antibodies, patients ultimately relapse. Selinexor is a first-in-class exportin-1 inhibitor with activity in these multiply relapsed and refractory patients. Although the current Food and Drug Administration (FDA) approval is for the doublet of Selinexor in combination with dexamethasone, ongoing clinical trials are evaluating a number of com

Proceedings of Réanimation 2020, the French Intensive Care Society International Congress.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

New strategies for stem cell mobilization.

Mobilized peripheral blood (PB) is widely used as source of stem cells (PBSCs) for autologous stem cell transplantation (ASCT). The use of cytokines, alone or in combination with chemotherapy (chemomobilization), is the most common strategy applied to mobilize and collect PBSCs. However, a significant proportion of cancer patients fail to mobilize enough PBSCs to proceed to ASCT. Plerixafor is a small molecule that reversibly and transiently disrupts the interaction between the chemokine receptor CXCR4 and its ligand CXCL12 (formerly known as stroma derived factor 1, SDF-1) leading to the rapi

Brave new world: expanding home care in stem cell transplantation and advanced therapies with new technologies.

Hematopoietic stem cell transplantation and cell therapies like CAR-T are costly, complex therapeutic procedures. Outpatient models, including at-home transplantation, have been developed, resulting in similar survival results, reduced costs, and increased patient satisfaction. The complexity and safety of the process can be addressed with various emerging technologies (artificial intelligence, wearable sensors, point-of-care analytical devices, drones, virtual assistants) that allow continuous patient monitoring and improved decision-making processes. Patients, caregivers, and staff can also

Совпадение в полном тексте источника
… Optimizing platelet transfusion through a personalized deep learning risk assessment system for demand management. Blood. (2023) 142:2315–26. doi: 10.1182/blood.2023021172 67. Maynard S, Farrington J, Alimam S, Evans H, Li K, Wong WK, et al. …

Modulation of the Immune Response by Deferasirox in Myelodysplastic Syndrome Patients.

Deferasirox (DFX) is an oral iron chelator used to reduce iron overload (IO) caused by frequent blood cell transfusions in anemic myelodysplastic syndrome (MDS) patients. To study the molecular mechanisms by which DFX improves outcome in MDS, we analyzed the global gene expression in untreated MDS patients and those who were given DFX treatment. The gene expression profiles of bone marrow CD34+ cells were assessed by whole-genome microarrays. Initially, differentially expressed genes (DEGs) were determined between patients with normal ferritin levels and those with IO to address the effect of

Pleuropulmonary Changes Induced by Drugs in Patients with Hematologic Diseases

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Взгляды на амбулаторное лечение би-специальных T-Cell-Worker терапий для нескольких миелом.

В последние несколько лет была разработана новая перспективная терапия под названием < < Участок Т-клеток > > (TCE), которая в настоящее время доступна во многих странах для пациентов с повторной или рефрактной множественной миеломой. Лица, занимающиеся деятельностью Т-клеток, связаны с устойчивыми показателями эффективности и беспрогрессивными льготами по выживанию у пациентов с хорошо обработанной миеломой. Однако такие осложнения, как синдром высвобождения цитокина (CRS), синдром нейротоксичности, связанный с иммунным эффектом клеток (ICANS), и инфекционные заболевания затрудняю

Repurposing Pharmaceuticals Previously Approved by Regulatory Agencies to Medically Counter Injuries Arising Either Early or Late Following Radiation Exposure.

The increasing risks of radiological or nuclear attacks or associated accidents have served to renew interest in developing radiation medical countermeasures. The development of prospective countermeasures and the subsequent gain of Food and Drug Administration (FDA) approval are invariably time consuming and expensive processes, especially in terms of generating essential human data. Due to the limited resources for drug development and the need for expedited drug approval, drug developers have turned, in part, to the strategy of repurposing agents for which safety and clinical data are alrea

Совпадение в полном тексте источника
… It is also recommended for immune thrombocytopenia and as an alternative to platelet transfusions ( Cheloff and Al-Samkari, 2019 ; Dlugosz-Danecka et al., 2019 ; Xu and Cai, 2019 ; Poordad et al., 2020 ). …

Transformation in pretreatment manifestations of Gaucher disease type 1 during two decades of alglucerase/imiglucerase enzyme replacement therapy in the International Collaborative Gaucher Group (ICGG) Gaucher Registry.

This study tests the hypothesis that the prevalence of severe clinical manifestations in Gaucher disease type 1 (GD1) patients at the time of treatment initiation has changed since alglucerase/imiglucerase enzyme replacement therapy (ERT) was approved in the United States (US) in 1991. US alglucerase/imiglucerase-treated GD1 patients from the International Collaborative Gaucher Group Gaucher Registry clinicaltrials.gov NCT00358943 were stratified by age at ERT initiation (<18, 18 to <50, ≥50 years), era of ERT initiation (1991-1995, 1996-2000, 2001-2005, 2006-2009), and splenectomy status pre-

Prognostic factors and outcomes of severe gastrointestinal GVHD after allogeneic hematopoietic cell transplantation.

We hypothesized that clinical risk factors could be identified within 2 weeks of onset of severe (stage 3 or 4) acute gut GVHD for identifying a patient population with a very poor outcome. Among 1462 patients who had allogeneic hematopoietic cell transplantation (HCT) between January 2000 and December 2005, 116 (7.9%) developed stage 3-4 gut GVHD. The median time for onset of stage 3-4 gut GVHD was 35 (4-135) days after allogeneic HCT. Eighty-five of the 116 patients (73%) had corticosteroid resistance before or within 2 weeks after the onset of stage 3-4 gut GVHD. Significant risk factors fo

Совпадение в полном тексте источника
… Platelet transfusions were given for platelet counts <10,000/mm 3 . …

Нейтропентия фебрилов отрицательно сказывается на результатах химиомобилизации у пациентов с множественной миеломой и повышает риск посттрансплантации инфекции у пациентов с лимфомой: реальные данные о мультицентрах в мире.

Точное воздействие фебриловой нейтроплании (ФН) во время химиомобилизации на сбор периферийных кровеносных стволовых клеток CD34+ и послетрансплантацию инфекции (инфекции) у пациентов с множественной миеломой (ММ) и лимфомой, проходящих автологическую трансплантацию стволовых клеток (ASCT). Записи реального мира 148 пациентов с диагнозом MM и 130 с лимфомой, которая прошла ACCT в октябре 2010 и январь 2024, были ретроспективно проанализированы. Все пациенты прошли химиотерапию с помощью гранулоцитовых колоний-стимулирующих факторов (G-CSF) для мобилизации стволовых клеток. Статистический анали

Multidisciplinary Care for the Prevention and Treatment of Venous Thromboembolism in Patients with Cancer-Associated Thrombosis (CAT): Impact of Educational Interventions on CAT-Related Events and on Patients' and Clinicians' Awareness.

Cancer is a leading cause of death. Venous thromboembolism (VTE) is an often-overlooked cause of morbidity and mortality in cancer patients that can be readily prevented and treated. Actions are needed to reduce the morbidity and mortality of patients with cancer-associated thrombosis (CAT). There is a need to increase awareness of the impact of CAT on cancer patients' morbidity and mortality, on their quality of life and to understand the importance of more effective preventions and treatments of VTE in cancer patients. Moreover, it is of great importance to systematically assess the risk of

Совпадение в полном тексте источника
… In the real world, there is a tendency to use a reduced dose of LMWH, in some cases associated to platelet transfusions. …

Acute Liver Failure due to Disseminated Varicella Zoster Infection.

Acute liver failure (ALF) can be due to numerous causes and result in fatality or necessitate liver transplantation if left untreated. Possible etiologies of ALF include ischemia, venous obstruction, medications, toxins, autoimmune hepatitis, metabolic and infectious causes including hepatitis A-E, varicella-zoster virus (VZV), cytomegalovirus (CMV), herpes simplex virus (HSV), Epstein-Barr virus (EBV), and adenovirus with VZV being the most rarely reported. Pathognomonic skin lesions facilitate diagnosis of VZV hepatitis, but definitive diagnosis is secured with liver biopsy, tissue histopath

Совпадение в полном тексте источника
… He was treated with fresh frozen plasma, platelet transfusions and was also diagnosed post mortem [ 5 ]. …